What Happened?
Shares of medical device company DexCom (NASDAQ: DXCM) jumped 7.3% in the morning session after it reported better-than-expected fourth-quarter 2025 financial results, beating analyst estimates for both revenue and earnings.
The company announced quarterly revenue of $1.26 billion, up 13.1% from the previous year. Its adjusted earnings per share came in at $0.68, surpassing the prior year's figure of $0.45 and topping Wall Street's forecasts. While DexCom's revenue and earnings surpassed expectations, the company's full-year revenue guidance was in line with analyst estimates. The positive investor reaction suggests a focus on the strong quarterly performance and profitability growth.
Is now the time to buy DexCom? Access our full analysis report here, it’s free.
What Is The Market Telling Us
DexCom’s shares are quite volatile and have had 15 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 4 months ago when the stock dropped 14.8% on the news that the company reported underwhelming earnings.
The company's revenue grew over 21% year-on-year to $1.21 billion, and its adjusted earnings per share of $0.61 also came in ahead of consensus estimates. DexCom lifted its full-year 2025 revenue forecast to approximately $4.64 billion. Despite these positive metrics, the stock's decline suggests investors were anticipating an even more robust performance and a more substantial guidance increase. The market's negative reaction indicates that the strong quarter was not enough to meet the high expectations priced into the stock, prompting a sell-off.
DexCom is up 5.1% since the beginning of the year, but at $69.94 per share, it is still trading 22.9% below its 52-week high of $90.75 from February 2025. Investors who bought $1,000 worth of DexCom’s shares 5 years ago would now be looking at an investment worth $691.86.
While Wall Street chases Nvidia at all-time highs, an under-the-radar semiconductor supplier is dominating a critical AI component these giants can’t build without. Click here to access our full research report, it’s free.
